Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential Profiles of IL-31- and IL-5/IL-13-Producing Cells Among Helper T Cells, With Subtle IL-31 Expression in Innate Lymphoid Cells.

Experimental dermatology·2025
Same author

Comprehensive Analysis of Type 2 Innate Lymphoid Cell (ILC2) Heterogeneity and Identification of CD81 as a Marker for Pathogenic IL-13<sup>+</sup> ILC2s in Atopic Dermatitis Skin.

Allergy·2025
Same author

Enhanced Innate Immunity Mediated by IL-36α in Atopic Dermatitis and Differences in Cytokine Profiles of Lymphocytes in the Skin and Draining Lymph Nodes.

Biomolecules·2025
Same author

Exploration of Metabolite Biomarkers to Predict the Efficacy of Dupilumab Treatment for Atopic Dermatitis.

Disease markers·2023
Same author

IL-33-induced keratoconjunctivitis is mediated by group 2 innate lymphoid cells in mice.

Allergology international : official journal of the Japanese Society of Allergology·2023
Same author

Arteriosclerosis Derived from Cutaneous Inflammation Is Ameliorated by the Deletion of IL-17A and IL-17F.

International journal of molecular sciences·2023

Related Experiment Video

Updated: Jan 20, 2026

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

10.1K

Interleukin-33 in atopic dermatitis.

Yasutomo Imai1

  • 1Department of Dermatology, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan.

Journal of Dermatological Science
|August 29, 2019
PubMed
Summary

Interleukin-33 (IL-33) drives atopic dermatitis (AD) by causing inflammation and skin barrier issues. Targeting IL-33 offers a new therapeutic approach for AD itch-scratch cycles.

Area of Science:

  • Immunology
  • Dermatology
  • Molecular Biology

Background:

  • Atopic dermatitis (AD) involves pruritus, skin barrier disruption, and type 2 inflammation.
  • Interleukin-33 (IL-33), an inflammatory cytokine, is overexpressed in AD keratinocytes.
  • IL-33 transgenic mice develop AD-like eczema, indicating IL-33's sufficiency in AD pathogenesis.

Purpose of the Study:

  • To elucidate the role of Interleukin-33 (IL-33) in the pathogenesis of atopic dermatitis (AD).
  • To investigate the mechanisms by which IL-33 contributes to AD symptoms, including pruritus and barrier dysfunction.
  • To explore IL-33 as a potential therapeutic target for AD.

Main Methods:

  • Utilized IL-33 transgenic mice to model AD development.
  • Analyzed cytokine production (IL-5, IL-13, IL-4, IL-31) by various immune cells (ILC2s, basophils).
Keywords:
Atopic dermatitisBasophilsGroup 2 innate lymphoid cells (ILC2s)IL-33IL-4

More Related Videos

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
06:29

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Published on: May 5, 2023

3.0K
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

25.0K

Related Experiment Videos

Last Updated: Jan 20, 2026

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

10.1K
Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
06:29

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Published on: May 5, 2023

3.0K
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

25.0K
  • Assessed skin barrier function by measuring filaggrin and claudin-1 expression.

    • Main Results:

    • IL-33 overexpression in keratinocytes is sufficient to induce AD-like eczema.
    • IL-33 activates group 2 innate lymphoid cells (ILC2s) and basophils, leading to type 2 cytokine release.
    • IL-33 induces IL-31, exacerbating pruritus and the itch-scratch cycle.
    • IL-33 impairs skin barrier function by reducing filaggrin and claudin-1 expression.
    • Scratching promotes IL-33 release, creating a positive feedback loop.

    Conclusions:

    • IL-33 is a central mediator in the atopic dermatitis itch-scratch cycle.
    • IL-33 plays a critical role in both inflammation and barrier dysfunction in AD.
    • Targeting IL-33 presents a promising strategy for novel AD therapeutics.